Biogen Enters into Agreement with TJ Biopharma for Felzartamab Assets in the Greater China RegionGlobeNewsWire • 04/20/26
These Alzheimer's drugs were supposed to revolutionize the way we fight the disease. The reality is more complicated.Market Watch • 04/18/26
3 Stocks With Upgraded Broker Ratings As Markets Hit All-Time HighZacks Investment Research • 04/16/26
This Healthcare Stock Has Made Long-Term Investors Rich -- Can It Keep Doing It?The Motley Fool • 04/16/26
Alloy Therapeutics Enters into Multi-Target Collaboration and License Agreement with Biogen for Use of Alloy's AntiClastic™ ASO PlatformBusiness Wire • 04/07/26
Biogen to Acquire Apellis for $5.6B to Strengthen Immunology PortfolioZacks Investment Research • 04/01/26
Biogen Inc. (BIIB) Discusses Proposed Acquisition of Apellis and Strategic Growth Objectives TranscriptSeeking Alpha • 03/31/26
Biogen to acquire Apellis Pharmaceuticals for $5.6B, adding C3 therapies to portfolioProactive Investors • 03/31/26
Biogen Snaps Up Apellis Pharma For $5.6 Billion, But Biogen Dives As Apellis SoarsInvestors Business Daily • 03/31/26
Biogen will acquire a drug company for $5.6 billion to expand work in kidney diseasesMarket Watch • 03/31/26
Biogen to Acquire Apellis, Enhancing the Company's Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into NephrologyGlobeNewsWire • 03/31/26
Biogen to Acquire Apellis, Enhancing the Company's Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology.GlobeNewsWire • 03/31/26
Biogen Stock Pops After FDA Approves New High-Dose Spinraza For Spinal Muscular AtrophyBenzinga • 03/30/26